股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD 4,000,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （ 於開曼群島註冊成立之有限公司） （股份代號︰269） 有關解決不發表意見的行動的季度更新 本公告由中國資源交通集團有限公司(「本公司」，連同其附屬公司，統稱「本 集團」)董事 (「董事」)會(「董事會」)根據香港聯合交易所有限公司(「聯交 所」)證券上市規則(「上市規則」)第13.09條及證券及期貨條例(香港法例第571 章)第 XIVA 部項下內幕消息條文(定義見上市規則)作出。 截至2025年7月31日，本公司較2025年4月30日進一步償還無擔保債務人民幣 13.81百萬元，剩餘未償還金額約為人民幣25.25百萬元，預計將於2025年9月26 日或之前全部清償。 於2025年7月11日，管理人与所有債務資本化債權人召開線上會議，就建議的債 務資本化實施方案及相關協議，以 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （ 於開曼群島註冊成立之有限公司） （股份代號︰269） 股東週年大會之投票結果 董事會欣然宣佈，所有於2025年8月28日舉行之股東週年大會上提呈之決議案已 獲正式通過 董事會欣然宣佈，該通告所載之所有決議案均已於2025年8月28日舉行之股東週 年大會上以投票表決方式獲正式通過。於股東週年大會日期，本公司已發行股份 為 10,644,093,185 股，而所有股東均有權出席大會並於會上投票贊成或反對該通 告所載所有普通及特別決議案。本公司於股東週年大會日期概無持有庫存股（包 括任何持有或存入中央結算系統的庫存股）。概無股份賦予股東權利出席股東週 年大會及須於會上放棄投票贊成任何決議案。概無股東須根據上市規則於股東週 年大會上對任何決議案放棄投票。概無股東於該通函中表明其有意對任 ...

Core Viewpoint - *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable paclitaxel (albumin-bound) product, which is now available for export sales in the United States [1] Company Summary - The company announced that its ANDA for injectable paclitaxel (100 mg/vial) has been approved by the U.S. FDA [1] - The product information will be disclosed in accordance with legal regulations, and investors are advised to refer to the company's announcements on designated media and the Giant Tide Information Network [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has recently received marketing authorization for its arginine vasopressin injection from the Australian Therapeutic Goods Administration (TGA) [1] Group 1: Company Developments - The company has obtained a significant regulatory approval for its arginine vasopressin injection, which is a critical step for market entry [1] - The product is available in a specification of 20 pressor units per 1 mL [1] Group 2: Market Insights - According to the Insight database, the global sales for arginine vasopressin injection are projected to reach approximately $72 million in 2024 [1] - The U.S. market is expected to contribute around $46 million to the total sales [1]

Core Viewpoint - China Resources Transportation (00269) reported a decline in revenue and a significant net loss for the fiscal year ending March 31, 2024, indicating financial challenges ahead [3]. Financial Performance - The company achieved a revenue of HKD 578 million, a year-on-year decrease of 2.61% [3]. - The net profit attributable to shareholders was a loss of HKD 338 million, compared to a profit of HKD 1.732 billion in the same period last year [3]. - The net cash flow from operating activities was HKD 187 million, down 82.12% year-on-year [3][18]. - The basic earnings per share stood at -HKD 0.03 [3]. Revenue Composition - The revenue composition for the fiscal year 2024-2025 shows that highway operations contributed HKD 576.9 million, while other operations contributed HKD 0.008 million [14]. Business Segments - The company operates primarily in three segments: highway operations, oil trading and services, and timber operations [8]. - The highway operations segment includes the operation, management, and maintenance of highways, along with investment in supporting facilities [8]. Cash Flow Analysis - The net cash flow from financing activities was -HKD 182 million, an increase of HKD 87.2 million year-on-year [18]. - The net cash flow from investing activities was -HKD 8.232 million, compared to -HKD 0.343 million in the previous year [18]. Asset and Liability Changes - As of March 31, 2025, prepayments increased by 139.9%, accounting for a 3.34 percentage point rise in total assets [28]. - Intangible assets decreased by 6.04%, leading to a 1.85 percentage point drop in total assets [28]. - Other payables (including interest and dividends) increased by 3.4%, contributing to a 6.41 percentage point rise in total assets [31]. Financial Ratios - The company reported a current ratio of 0.03 and a quick ratio of 0.03 during the reporting period [35].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 股東週年大會通告 茲通告中國資源交通集團有限公司（「本公司」）謹訂於 2025 年 8 月 28 日（星期四）上 午十一時正假座中國廣東省深圳市福田區金田路榮超經貿中心 2408 室舉行股東週年大會 （「股東週年大會」），藉以考慮下列決議案： 作為普通事項 A. 考慮及酌情通過下列決議案（ 考慮及酌情通過下列決議案（不論有否經修訂 不論有否經修訂 不論有否經修訂）作為普通決議案 作為普通決議案: 「動議︰ CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號︰269） 作為特別事項 1. 省覽及考慮截至 2025 年 3 月 31 日止年度之經審核財務報表及本公司董事 （「董事」）會與核數師報告書。 2. 重選段景泉先生為執行董事，以及井寶利先生與包良明先生為獨立非執行董事。 3. 授權董 ...

此 乃 要 件 請 即 處 理 閣下如 對本通函任何方面或應採取之行動有任何疑問，應諮詢股票經紀、銀行經 理、律師、專業會計師或其他專業顧問。 閣下如已將名 下 之 中國資源交通集團有限公司股 份全 部 售出或轉讓，應立即將本 通函連同隨附之代表委任表格送交買主或承讓人，或經手買賣或轉讓之銀行、股 票經紀或其他代理商，以便轉交買主或承讓人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部 或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA RESOURCES AND TRANSPORTATION GROUP LIMITED 中國資源交通集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：269） (1) 建議授出發行新股份 及購回股份之一般授權 及購回股份之一般授權 購回股份之一般授權； (2) 建議重選董事； 建議重選董事； 及 (3) 股東週年大會通告 股東週年大會通告 本 公 司 謹 訂 於 2025年8月2 ...

Revenue and Operations - For the year ended March 31, 2025, the Group's revenue was primarily driven by toll income from the 265-kilometer Zhunxing Expressway, which is indirectly held at 86.87% by the Company[20]. - The Group's operations also include compressed natural gas (CNG) gas stations and the growing and sales of forage and agricultural products, diversifying its revenue streams[20]. - For the year ended 31 March 2025, Zhunxing Expressway recorded an accumulated toll income of approximately HK$576.86 million (approximately RMB535.01 million), representing a decrease of approximately 2.82% from the previous year[22]. - The average daily toll revenue for Zhunxing Expressway in 2025 was RMB 1.46 million (HK$ 1.58 million), down 2.01% from RMB 1.49 million (HK$ 1.63 million) in 2024[24]. - Toll income from expressway operations was approximately HK$576.86 million, representing a decrease of about 2.82% compared to HK$593.15 million in 2024, primarily due to local factors and currency exchange rate fluctuations[34]. - The Group's revenue was recognized under two reportable segments: expressway operation and other operations, contributing approximately HK$576.86 million and HK$0.80 million, respectively[33]. Financial Performance - For the year ended 31 March 2025, the Group's revenue was approximately HK$577.66 million, a decrease of about 2.61% from HK$593.15 million in the previous year[33]. - The Group's cost of sales increased by approximately 16.12% to HK$432.81 million from HK$372.74 million in the previous year, mainly due to higher repairs and maintenance costs related to expressway operations[38]. - Gross profit for the year was approximately HK$144.85 million, down from HK$220.41 million in 2024[39]. - Adjusted EBITDA decreased by approximately 21.64% to HK$379.33 million from HK$484.06 million in the previous year, primarily driven by increased maintenance costs[40]. - The Group recorded a loss before taxation of HK$342.61 million for the year, compared to a profit of HK$2,048.11 million in 2024[48]. - The Group's net loss for the year ended 31 March 2025 was approximately HK$342.61 million, a decrease of approximately 116.73% from a net profit of approximately HK$2,048.11 million for the year ended 31 March 2024[66]. Debt and Restructuring - The restructuring proposal for Zhunxing was approved by the Court on September 26, 2023, with total debts confirmed by the Administrator amounting to approximately RMB13.58 billion[102]. - The Group currently holds an 86.87% equity interest in Zhunxing, which remains unchanged as the restructuring is still in progress[109]. - The Group's outstanding borrowings amounted to approximately HK$9,115.96 million, representing about 47.80% of the total liabilities[74][77]. - The Group's net debt position was approximately HK$13,031.91 million as of March 31, 2025, compared to HK$12,765.07 million as of March 31, 2024[75]. - The Group's debt ratio was approximately 315.40% as of March 31, 2025, an increase from 302.60% in the previous year[75]. - The Group is negotiating with banks and creditors for debt restructuring, but no agreements have been reached as of the report date[140]. Market and Economic Conditions - The stable growth of the global economy is projected to increase transportation demand, thereby boosting toll expressway traffic and revenues[11]. - The toll expressway industry's defensive characteristics are becoming more attractive to investors in a low-interest-rate environment, enhancing the investment value of toll expressways[12]. - The PRC government is implementing measures to expand coal supply and stabilize coal prices, which will support the steady growth of the coal industry and, consequently, toll revenue from Zhunxing Expressway[13]. - The general outlook for the business environment remains challenging due to the slowdown of China's economy and energy control policies[130]. - The PRC is promoting highway network construction to stimulate economic development, which is expected to positively impact traffic volume and toll income for Zhunxing Expressway[131]. Management and Strategy - The management team is committed to improving traffic safety service levels and enhancing working capital conditions to ensure the Group's continued development[14]. - Zhunxing plans to implement a differentiated toll strategy to attract various types of vehicles, based on the national toll collection policy[28]. - The company aims to enhance road maintenance and safety through a 24-hour patrol system to improve service levels and emergency response[28]. - The Group is finalizing the restructuring, with certain claims against Zhunxing discharged and compromised in full[109]. - The Group is exploring various avenues to improve liquidity, including rights issues, asset disposals, and identifying new purchasers for Zhunxing[136]. Risks and Compliance - The Group is exposed to financial risks including interest rate risk, foreign currency risk, credit risk, liquidity risk, and equity price risk[149]. - The Group has been implementing measures to improve its liquidity position as detailed in the consolidated financial statements[150]. - The Group's expressway operations may be adversely affected by natural disasters and outbreaks of contagious diseases, impacting traffic volume and toll revenue[155]. - The Group has not been aware of any non-compliance with applicable laws and regulations that had a significant impact during the year ended March 31, 2025[160]. Audit and Financial Reporting - The auditor issued a disclaimer of opinion on the consolidated financial statements for the year ended March 31, 2025, due to multiple material uncertainties[88][90]. - The Auditor did not express an opinion on the consolidated financial statements for the year ended 31 March 2025 due to uncertainties related to going concern[137]. - The Board expects that the consolidated financial statement for the year ended March 31, 2026, will be free of Audit Qualification if all measures are successfully implemented[143]. - As of March 31, 2025, the audit opinion remains unresolved due to delays in debt restructuring and lack of significant agreements with creditors or potential buyers[144].

金融界消息 截至2025年7月31日收盘，*ST双成（002693）报收于8.3元，上涨4.4%，换手率7.15%，成 交量29.40万手，成交金额2.44亿元。 资金流向方面，今日主力资金净流入3752.16万元，占比成交额15.39%。其中，超大单净流入1533.26万 元、占成交额6.29%，大单净流入2218.90万元、占成交额9.1%，中单净流出流出1622.48万元、占成交 额6.66%，小单净流出2129.69万元、占成交额8.74%。 天眼查商业履历信息显示，海南双成药业股份有限公司，成立于2000年，位于海口市，是一家以从事医 药制造业为主的企业。企业注册资本41468.975万人民币，实缴资本41468.975万人民币。公司法定代表 人为王成栋。 通过天眼查大数据分析，海南双成药业股份有限公司共对外投资了2家企业，参与招投标项目141次，知 识产权方面有商标信息28条，专利信息15条，此外企业还拥有行政许可301个。 来源：金融界 *ST双成最新一期业绩显示，截至2025中报，公司营业总收入8412.21万元、同比减少11.35%，归属净利 润1846.66万元，同比减少8.97%，扣非净 ...